COHERUS BIOSCIENCES INC. - COMMON STOCK

0,9201

14-марта-25 16:45:00

15 мин. задержка

Акции

+0,0295

+3,31%

Сегодняшний диапазон

0,8955 - 0,9994

ISIN

N/A

Источник

NASDAQ

Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan

09 май 2024 07:30:00 Источник Nasdaq GlobeNewswire
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer

08 май 2024 09:00:00 Источник Nasdaq GlobeNewswire
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024

01 май 2024 16:30:00 Источник Nasdaq GlobeNewswire
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 апр 2024 10:02:18 Источник Nasdaq GlobeNewswire
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting

08 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update

13 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024

05 мар 2024 16:01:00 Источник Nasdaq GlobeNewswire
Coherus Completes Divestiture of Ophthalmology Franchise

04 мар 2024 01:00:00 Источник Nasdaq GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants

23 фев 2024 17:33:13 Источник Nasdaq GlobeNewswire
Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

21 фев 2024 08:30:00 Источник Nasdaq GlobeNewswire
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP

05 фев 2024 08:00:01 Источник Nasdaq GlobeNewswire
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

22 янв 2024 01:15:00 Источник Nasdaq GlobeNewswire
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

18 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 09:00:00 Источник Nasdaq GlobeNewswire
Coherus Announces U.S. Launch of LOQTORZI™

02 янв 2024 08:29:00 Источник Nasdaq GlobeNewswire
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

26 дек 2023 16:01:00 Источник Nasdaq GlobeNewswire
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

11 дек 2023 08:30:00 Источник Nasdaq GlobeNewswire
Coherus BioSciences Announces CFO Transition Plans

07 дек 2023 17:55:48 Источник Nasdaq GlobeNewswire
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress

06 дек 2023 04:00:00 Источник Nasdaq GlobeNewswire
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI™ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association

28 ноя 2023 11:16:23 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.